THBS2 as a prognostic biomarker for patients diagnosed with metastatic pancreatic ductal adenocarcinoma

Patients newly diagnosed with metastatic pancreatic ductal adenocarcinoma generally have poor survival, with heterogeneous rates of progression. Biomarkers that could predict progression and/or survival would help inform patients and providers as they make care decisions. In a previous retrospective...

Descripción completa

Detalles Bibliográficos
Autores principales: Gimotty, Phyllis A., Till, Jacob E., Udgata, Shirsa, Takenaka, Naomi, Yee, Stephanie S., LaRiviere, Michael J., O’Hara, Mark H., Reiss, Kim A., O'Dwyer, Peter, Katona, Bryson W., Herman, Daniel, Carpenter, Erica L., Zaret, Kenneth S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555682/
https://www.ncbi.nlm.nih.gov/pubmed/34733417
http://dx.doi.org/10.18632/oncotarget.28099

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555682/
https://www.ncbi.nlm.nih.gov/pubmed/34733417
http://dx.doi.org/10.18632/oncotarget.28099

Ejemplares similares